WST
BuyPremium GrowerFLAGWest Pharmaceutical Services, Inc. · Healthcare · United States · $23.7B · Avg Vol: $191M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
West Pharmaceutical has strong quality Q76 and momentum M79 with a buyback retiring 2.51% of shares, but value at V18 is well below the calibrated floor, so stage one fails.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT WEST PHARMACEUTICAL SERVICES, INC.
Read
West Pharmaceutical Services is a global leader in designing and manufacturing high-quality containment and delivery systems for injectable drugs and other healthcare products, including stoppers, seals, and syringe components. The company's competitive moat is built upon its critical position as a trusted partner to pharmaceutical companies, extensive regulatory expertise, and proprietary technologies, which create high switching costs for drug packaging. West is a niche market leader, integral to the biopharmaceutical supply chain.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9B | 2.9B | 2.9B | 3.1B | 2.1% | 3.3B | 3.4B | 3.6B | 8.0% |
| EPS | 7.87 | 7.98 | 6.75 | 6.83 | -4.6% | 7.81 | 8.40 | 9.35 | 17.0% |
| Shares | 74.1M | 73.5M | 72.3M | 72.0M | -2.8% | 70.4M | — | — | — |
| Debt | 317.9M | 309.0M | 302.3M | 321.1M | 0.3% | 316.5M | — | — | — |
| Equity | 2.7B | 2.9B | 2.7B | 3.2B | 5.8% | — | — | — | — |
| Op CF | 724.0M | 776.5M | 653.4M | 754.8M | 1.4% | 662.2M | — | — | — |
| Inv CF | -288.2M | -368.7M | -378.7M | -285.9M | — | — | — | — | — |
| Fin CF | -293.6M | -459.6M | -622.6M | -185.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WST | West Pharmaceutical Services, Inc.(you) | $23.7B | 74 | Buy |
| BAX | Baxter International Inc. | $13.5B | 73 | Buy |
| SOLV | Solventum Corporation | $15.5B | 83 | Strong Buy |
| BDX | Becton, Dickinson and Company | $51.6B | 77 | Buy |
| RMD | ResMed Inc. | $34.7B | 87 | Strong Buy |
| ATR | AptarGroup, Inc. | $8.5B | 74 | Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
| ALGN | Align Technology, Inc. | $11.2B | 85 | Strong Buy |
| TFX | Teleflex Incorporated | $5.9B | 66 | Buy |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.